Li Deping, Yu Dongmin, Li Yan, Yang Renze
Department of Pharmacy, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
Department of Breast Disease Comprehensive Center, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
Eur J Med Chem. 2022 Dec 15;244:114838. doi: 10.1016/j.ejmech.2022.114838. Epub 2022 Oct 14.
Proteolysis targeting chimera (PROTAC) technology, one of the targeted protein degradation technologies, has drawn marked attention from researchers of both academia and industry in recent years. After over two decades of development, the literature on it has proliferated. In order to better grasp the frontiers and hot spots of PROTAC, this bibliometric analysis was carried out. The articles and reviews regarding PROTAC were culled from the Web of Science Core Collection. General information and the trend of publication outputs, countries/regions, authors, journals, influential papers, and keywords in this field were visually analyzed using CtieSpace, VOSviewer, or Excel software. As a result, a total of 808 publications were included. The number of papers regarding PROTAC significantly increased yearly. These papers mainly come from 45 countries/regions led by the USA and China. 3886 authors were identified participating in these studies, among which Craig M. Crews had the most significant number and influential articles. Journal of Medicinal Chemistry and European Journal of Medicinal Chemistry are the two journals with the most papers. After analysis, the most influential papers were identified in the area, including highly cited papers, references with citation burst, and high co-citated papers. The most common keywords including cancer, E3 ligase, drug discovery, epigenetic, resistance, and so on, represent the current and developing areas of study. BRDs, androgen receptor (AR), HDACs, estrogen receptor (ER), EGFR, CDKs, and KRAS are the most common targets. At last, frontiers and challenges of PROTAC were discussed through the bibliometric analysis. This paper will be helpful for better understanding the frontiers and hotspots of PROTAC.
蛋白酶靶向嵌合体(PROTAC)技术作为靶向蛋白质降解技术之一,近年来受到了学术界和工业界研究人员的广泛关注。经过二十多年的发展,关于该技术的文献大量涌现。为了更好地把握PROTAC的前沿和热点,进行了这项文献计量分析。从科学网核心合集筛选出了关于PROTAC的文章和综述。使用CtieSpace、VOSviewer或Excel软件对该领域的一般信息、发表产出趋势、国家/地区、作者、期刊、有影响力的论文和关键词进行了可视化分析。结果,共纳入了808篇出版物。关于PROTAC的论文数量逐年显著增加。这些论文主要来自以美国和中国为首的45个国家/地区。确定有3886名作者参与了这些研究,其中克雷格·M·克鲁斯的论文数量最多且影响力最大。《药物化学杂志》和《欧洲药物化学杂志》是发表论文最多的两本期刊。经过分析,确定了该领域最具影响力的论文,包括高被引论文、具有引用爆发的参考文献和高共被引论文。最常见的关键词包括癌症、E3连接酶、药物发现、表观遗传学、耐药性等,代表了当前和正在发展的研究领域。溴结构域蛋白(BRDs)、雄激素受体(AR)、组蛋白去乙酰化酶(HDACs)、雌激素受体(ER)、表皮生长因子受体(EGFR)、细胞周期蛋白依赖性激酶(CDKs)和KRAS是最常见的靶点。最后,通过文献计量分析讨论了PROTAC的前沿和挑战。本文将有助于更好地理解PROTAC的前沿和热点。
Eur J Med Chem. 2022-12-15
Front Pharmacol. 2023-11-13
Front Endocrinol (Lausanne). 2023
Front Biosci (Landmark Ed). 2022-8-31
Front Immunol. 2021
Medicine (Baltimore). 2025-8-29
Commun Chem. 2025-7-29
Hum Vaccin Immunother. 2025-12
Front Oncol. 2025-6-3
Medicine (Baltimore). 2025-6-13